---
document_datetime: 2025-12-29 12:02:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/elrexfio.html
document_name: elrexfio.html
version: success
processing_time: 0.1191288
conversion_datetime: 2025-12-30 03:35:21.213544
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Elrexfio

[RSS](/en/individual-human-medicine.xml/77408)

##### Authorised

This medicine is authorised for use in the European Union

elranatamab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Elrexfio](#news-on)
- [More information on Elrexfio](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Elrexfio is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory). It can be used in adults who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody, and whose cancer has worsened since the last treatment.

Elrexfio contains the active substance elranatamab.

Expand section

Collapse section

## How is Elrexfio used?

Elrexfio can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in the management of multiple myeloma.

The medicine must be given by adequately trained medical personnel in a location with appropriate medical support to manage possible severe side effects such as cytokine release syndrome (CRS, a potentially life-threatening overactivation of the immune system with fever, shortness of breath, low blood pressure and headache) and immune effector cell-associated neurotoxicity syndrome (ICANS, a neurological disorder with symptoms including problems with speech and writing, confusion and reduced level of consciousness).

Elrexfio is given as an injection under the skin. In the first week of treatment, injections are given on days 1 and 4 at increasing doses and then weekly up to week 24. Patients who respond to treatment can then continue with one injection every two weeks.

To reduce the risk of developing CRS, patients are given medicines one hour before receiving the first three doses of Elrexfio. Patients should be monitored for symptoms of CRS or ICANS for 48 hours after the first two doses of Elrexfio.

Treatment should continue for as long as the patient benefits from it or until side effects become unmanageable. The doctor may delay doses if certain side effects occur or stop treatment altogether for certain severe side effects. For more information about using Elrexfio, see the package leaflet or contact your doctor or pharmacist.

## How does Elrexfio work?

The active substance in Elrexfio, elranatamab, is a bispecific antibody (a type of protein). It is designed to recognise and attach to two targets simultaneously: the B cell maturation antigen (BCMA) on the surface of cancer cells and CD3 on the surface of T cells (cells in the immune system). By attaching to these targets, this medicine brings the cancer cells and T cells together. This activates the T cells, which then kill myeloma cells.

## What benefits of Elrexfio have been shown in studies?

Elrexfio was shown to be effective at clearing the cancer in an ongoing study. This study involved 123 patients with multiple myeloma whose disease had stopped responding to and had come back after three previous therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody). Patients had not received prior treatment targeting BCMA on myeloma cells. In this study, 61% (75 of 123) of patients responded to treatment with Elrexfio, including 36% (44 out of 123) who had a complete response (no signs of cancer). The study did not compare Elrexfio with other medicines or placebo (a dummy treatment).

## What are the risks associated with Elrexfio?

For the full list of side effects and restrictions with Elrexfio, see the package leaflet.

The most common side effects with Elrexfio (which may affect more than 1 in 5 people) include CRS, anaemia (low levels of red blood cells), neutropenia (low levels of neutrophils, a type of white blood cell), fatigue (tiredness), infection of the upper respiratory tract (nose and throat), injection site reactions, diarrhoea, pneumonia (infection of the lungs), thrombocytopenia (low levels of blood platelets, components that help the blood to clot), lymphopenia (low levels of lymphocytes, a type of white blood cell), decreased appetite, fever, rash, arthralgia (joint pain), hypokalaemia (low blood potassium levels), nausea (feeling sick) and dry skin.

Serious side effects include pneumonia, sepsis (blood poisoning), CRS, anaemia, upper respiratory tract infection, infection of the urinary tract (parts of the body that collect and pass out urine), febrile neutropenia (low levels of white blood cells with fever), dyspnoea (difficulty breathing) and fever.

## Why is Elrexfio authorised in the EU?

At the time of approval, the European Medicines Agency considered that there was an unmet medical need for patients with multiple myeloma whose condition no longer improves with available therapies. These patients, who have limited treatment options, had a clinically meaningful response to treatment with Elrexfio, as shown by the proportion of patients who had either a complete or partial response within the main study. Overall, the safety profile was considered acceptable; the Agency considered that important safety concerns, such as CRS and ICANS, are reversible and manageable with standard treatment. Due to the lack of a comparator and the short duration of follow-up of patients in the main study, a number of uncertainties remain regarding the safety and effectiveness of Elrexfio; it is expected that these will be addressed by further data that will be submitted by the company.

Elrexfio has been given 'conditional authorisation'. This means that that the Agency decided that the benefits of Elrexfio are greater than its risks, but the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the European Medicines Agency will review any new information that becomes available until comprehensive data are available and this overview will be updated as necessary.

Since Elrexfio was given conditional authorisation, at the time of approval the company marketing Elrexfio was required to submit the final results of the ongoing study in patients with multiple myeloma who were treated with Elrexfio. In addition, they have to provide data from a study that compares the effectiveness of both Elrexfio given on its own and in combination with daratumumab (another cancer medicine) with that of other treatments currently authorised for the same use.

## What measures are being taken to ensure the safe and effective use of Elrexfio?

The company that markets Elrexfio will provide patients with an alert card that contains information about the risk of CRS and side effects affecting the nervous system, including ICANS. The alert card also notifies healthcare professionals that the patient is receiving treatment with Elrexfio.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elrexfio have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Elrexfio are continuously monitored. Suspected side effects reported with Elrexfio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Elrexfio

Elrexfio received a conditional marketing authorisation valid throughout the EU on 07 December 2023.

Elrexfio : EPAR - Medicine overview

Reference Number: EMA/556693/2023

English (EN) (125.67 KB - PDF)

**First published:** 25/01/2024

[View](/en/documents/overview/elrexfio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-226)

български (BG) (151.03 KB - PDF)

**First published:**

25/01/2024

[View](/bg/documents/overview/elrexfio-epar-medicine-overview_bg.pdf)

español (ES) (125.46 KB - PDF)

**First published:**

25/01/2024

[View](/es/documents/overview/elrexfio-epar-medicine-overview_es.pdf)

čeština (CS) (149.92 KB - PDF)

**First published:**

25/01/2024

[View](/cs/documents/overview/elrexfio-epar-medicine-overview_cs.pdf)

dansk (DA) (124.19 KB - PDF)

**First published:**

25/01/2024

[View](/da/documents/overview/elrexfio-epar-medicine-overview_da.pdf)

Deutsch (DE) (128.6 KB - PDF)

**First published:**

25/01/2024

[View](/de/documents/overview/elrexfio-epar-medicine-overview_de.pdf)

eesti keel (ET) (123.24 KB - PDF)

**First published:**

25/01/2024

[View](/et/documents/overview/elrexfio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.84 KB - PDF)

**First published:**

25/01/2024

[View](/el/documents/overview/elrexfio-epar-medicine-overview_el.pdf)

français (FR) (126.68 KB - PDF)

**First published:**

25/01/2024

[View](/fr/documents/overview/elrexfio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (152.64 KB - PDF)

**First published:**

25/01/2024

[View](/hr/documents/overview/elrexfio-epar-medicine-overview_hr.pdf)

italiano (IT) (123.99 KB - PDF)

**First published:**

25/01/2024

[View](/it/documents/overview/elrexfio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (158.74 KB - PDF)

**First published:**

25/01/2024

[View](/lv/documents/overview/elrexfio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (149.69 KB - PDF)

**First published:**

25/01/2024

[View](/lt/documents/overview/elrexfio-epar-medicine-overview_lt.pdf)

magyar (HU) (149.5 KB - PDF)

**First published:**

25/01/2024

[View](/hu/documents/overview/elrexfio-epar-medicine-overview_hu.pdf)

Malti (MT) (152.7 KB - PDF)

**First published:**

25/01/2024

[View](/mt/documents/overview/elrexfio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.91 KB - PDF)

**First published:**

25/01/2024

[View](/nl/documents/overview/elrexfio-epar-medicine-overview_nl.pdf)

polski (PL) (152.89 KB - PDF)

**First published:**

25/01/2024

[View](/pl/documents/overview/elrexfio-epar-medicine-overview_pl.pdf)

português (PT) (126.05 KB - PDF)

**First published:**

25/01/2024

[View](/pt/documents/overview/elrexfio-epar-medicine-overview_pt.pdf)

română (RO) (147.86 KB - PDF)

**First published:**

25/01/2024

[View](/ro/documents/overview/elrexfio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (148.44 KB - PDF)

**First published:**

25/01/2024

[View](/sk/documents/overview/elrexfio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (148.51 KB - PDF)

**First published:**

25/01/2024

[View](/sl/documents/overview/elrexfio-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.87 KB - PDF)

**First published:**

25/01/2024

[View](/fi/documents/overview/elrexfio-epar-medicine-overview_fi.pdf)

svenska (SV) (123.6 KB - PDF)

**First published:**

25/01/2024

[View](/sv/documents/overview/elrexfio-epar-medicine-overview_sv.pdf)

Elrexfio : EPAR - Risk management plan

English (EN) (1003.4 KB - PDF)

**First published:** 25/01/2024

**Last updated:** 16/07/2025

[View](/en/documents/rmp/elrexfio-epar-risk-management-plan_en.pdf)

## Product information

Elrexfio : EPAR - Product information

English (EN) (261.79 KB - PDF)

**First published:** 25/01/2024

**Last updated:** 17/09/2025

[View](/en/documents/product-information/elrexfio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-782)

български (BG) (294 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/bg/documents/product-information/elrexfio-epar-product-information_bg.pdf)

español (ES) (278.39 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/es/documents/product-information/elrexfio-epar-product-information_es.pdf)

čeština (CS) (278.25 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/cs/documents/product-information/elrexfio-epar-product-information_cs.pdf)

dansk (DA) (264.72 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/da/documents/product-information/elrexfio-epar-product-information_da.pdf)

Deutsch (DE) (570.9 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

07/11/2025

[View](/de/documents/product-information/elrexfio-epar-product-information_de.pdf)

eesti keel (ET) (272.29 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/et/documents/product-information/elrexfio-epar-product-information_et.pdf)

ελληνικά (EL) (300.94 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/el/documents/product-information/elrexfio-epar-product-information_el.pdf)

français (FR) (282.99 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/fr/documents/product-information/elrexfio-epar-product-information_fr.pdf)

hrvatski (HR) (295.6 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/hr/documents/product-information/elrexfio-epar-product-information_hr.pdf)

íslenska (IS) (267.64 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/is/documents/product-information/elrexfio-epar-product-information_is.pdf)

italiano (IT) (269.72 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/it/documents/product-information/elrexfio-epar-product-information_it.pdf)

latviešu valoda (LV) (279.83 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/lv/documents/product-information/elrexfio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (269.59 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/lt/documents/product-information/elrexfio-epar-product-information_lt.pdf)

magyar (HU) (281.68 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/hu/documents/product-information/elrexfio-epar-product-information_hu.pdf)

Malti (MT) (320.28 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/mt/documents/product-information/elrexfio-epar-product-information_mt.pdf)

Nederlands (NL) (277.14 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/nl/documents/product-information/elrexfio-epar-product-information_nl.pdf)

norsk (NO) (266.2 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/no/documents/product-information/elrexfio-epar-product-information_no.pdf)

polski (PL) (293.89 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/pl/documents/product-information/elrexfio-epar-product-information_pl.pdf)

português (PT) (275.35 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/pt/documents/product-information/elrexfio-epar-product-information_pt.pdf)

română (RO) (279.52 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/ro/documents/product-information/elrexfio-epar-product-information_ro.pdf)

slovenčina (SK) (282.9 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/sk/documents/product-information/elrexfio-epar-product-information_sk.pdf)

slovenščina (SL) (272.17 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/sl/documents/product-information/elrexfio-epar-product-information_sl.pdf)

Suomi (FI) (272.17 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/fi/documents/product-information/elrexfio-epar-product-information_fi.pdf)

svenska (SV) (266.72 KB - PDF)

**First published:**

25/01/2024

**Last updated:**

17/09/2025

[View](/sv/documents/product-information/elrexfio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000278463 11/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Elrexfio : EPAR - All authorised presentations

English (EN) (25.61 KB - PDF)

**First published:** 25/01/2024

[View](/en/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-216)

български (BG) (27.28 KB - PDF)

**First published:**

25/01/2024

[View](/bg/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.57 KB - PDF)

**First published:**

25/01/2024

[View](/es/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (26.99 KB - PDF)

**First published:**

25/01/2024

[View](/cs/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.33 KB - PDF)

**First published:**

25/01/2024

[View](/da/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.63 KB - PDF)

**First published:**

25/01/2024

[View](/de/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.04 KB - PDF)

**First published:**

25/01/2024

[View](/et/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (25.46 KB - PDF)

**First published:**

25/01/2024

[View](/el/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_el.pdf)

français (FR) (25.51 KB - PDF)

**First published:**

25/01/2024

[View](/fr/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.7 KB - PDF)

**First published:**

25/01/2024

[View](/hr/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.02 KB - PDF)

**First published:**

25/01/2024

[View](/is/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.08 KB - PDF)

**First published:**

25/01/2024

[View](/it/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.04 KB - PDF)

**First published:**

25/01/2024

[View](/lv/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (25.36 KB - PDF)

**First published:**

25/01/2024

[View](/lt/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.77 KB - PDF)

**First published:**

25/01/2024

[View](/hu/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.95 KB - PDF)

**First published:**

25/01/2024

[View](/mt/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.35 KB - PDF)

**First published:**

25/01/2024

[View](/nl/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.44 KB - PDF)

**First published:**

25/01/2024

[View](/no/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.55 KB - PDF)

**First published:**

25/01/2024

[View](/pl/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.86 KB - PDF)

**First published:**

25/01/2024

[View](/pt/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_pt.pdf)

română (RO) (25.76 KB - PDF)

**First published:**

25/01/2024

[View](/ro/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.93 KB - PDF)

**First published:**

25/01/2024

[View](/sk/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.09 KB - PDF)

**First published:**

25/01/2024

[View](/sl/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.91 KB - PDF)

**First published:**

25/01/2024

[View](/fi/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.22 KB - PDF)

**First published:**

25/01/2024

[View](/sv/documents/all-authorised-presentations/elrexfio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Elrexfio Active substance elranatamab International non-proprietary name (INN) or common name elranatamab Therapeutic area (MeSH) Multiple Myeloma

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

## Authorisation details

EMA product number EMEA/H/C/005908

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Pleinlaan 17

Opinion adopted 12/10/2023 Marketing authorisation issued 07/12/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Elrexfio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (326.65 KB - PDF)

**First published:** 07/04/2025

**Last updated:** 17/09/2025

[View](/en/documents/procedural-steps-after/elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Elrexfio : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (163.34 KB - PDF)

**First published:** 22/07/2024

**Last updated:** 16/07/2025

[View](/en/documents/procedural-steps-after/elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Elrexfio : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000147440

English (EN) (458.77 KB - PDF)

**First published:** 25/01/2024

[View](/en/documents/orphan-maintenance-report/elrexfio-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Elrexfio : EPAR - Public assessment report

Adopted

Reference Number: EMA/544323/2023

English (EN) (4.72 MB - PDF)

**First published:** 25/01/2024

[View](/en/documents/assessment-report/elrexfio-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Elrexfio

Adopted

Reference Number: EMA/CHMP/436072/2023

English (EN) (153.13 KB - PDF)

**First published:** 13/10/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-elrexfio_en.pdf)

#### News on Elrexfio

[New treatment option for heavily pre-treated multiple myeloma patients](/en/news/new-treatment-option-heavily-pre-treated-multiple-myeloma-patients) 13/10/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

#### More information on Elrexfio

- [Real-World (RW) Elranatamab Administration: Step Up Dosing (SUD), Treatment Patterns, and Healthcare Resource Utilization (HCRU) in Japan MDV Data (SUMMIT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000503)
- [Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000229)
- [Administration of Elranatamab In the Real-World: Treatment Patterns, Healthcare Resource Utilization, Costs, Effectiveness, anD SafEty (ALTITUDE-2) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000293)
- [An International, Multicenter, Non-interventional Post-Authorization Safety Study to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated in Real-World Settings (MagnetisMM-16) - post-authorisation study](https://catalogues.ema.europa.eu/study/106402)
- [A french AMBispective, multisite, non-interventional Real-life effectiveness and safety of ELranatanab for the treatment of patients with relapse or refractory multiple myelomA (RRMM) - (AMbreLA) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000074)

**This page was last updated on** 17/09/2025

## Share this page

[Back to top](#main-content)